News

October 16, 2025 Imbria Pharmaceuticals Partners with Hypertrophic Cardiomyopathy Association to Support FORTITUDE-HCM Trial Evaluating Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy Partnership further supports trial recruitment; FORTITUDE-HCM to be highlighted at upcoming HCMA Annual Patient Meeting   Enrollment underway for the global, multicenter, double-blind Phase 2b trial assessing efficacy and safety of ninerafaxstat in patients with […]

September 16, 2025 Imbria Pharmaceuticals Strengthens Leadership with New Board and Key Clinical Appointments Pavan Cheruvu, MD, will serve as Independent Chair of the Board of Directors   James Januzzi, MD, appointed to Senior Research Advisor and Scientific Advisory Board Chair    BOSTON, Mass., September 16, 2025 — Imbria Pharmaceuticals, Inc., (“Imbria”), a clinical-stage company transforming

August 19, 2025 Imbria Pharmaceuticals Appoints Physician-Scientist Albert M. Kim, MD, PhD, as Chief Medical Officer BOSTON, Mass., August 19, 2025 – Imbria Pharmaceuticals, Inc., (“Imbria”), a clinical-stage company revolutionizing cardiovascular disease treatment by targeting cardiac energy metabolism, today announced the appointment of physician-scientist, Albert M. Kim, MD, PhD, FACC, FHRS, as Chief Medical Officer

April 10, 2025 Imbria Pharmaceuticals Raises $57.5M Series B Financing Round and Appoints Alvin Shih, MD as CEO Led by new investor Deep Track Capital, with participation from AN Ventures, Catalio Capital Management, Cytokinetics, Inc. and existing investors RA Capital Management and SV Health Investors   Proceeds to support advancement of ninerafaxstat for the treatment